KRAS G12C Emerges as New Potential Target in Non-Small Cell Lung Cancer
Edward B. Garon, MD, discusses an exciting new agent, or class of agents, that are under evaluation as treatment of patients with non-small cell lung cancer.
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses an exciting new agent, or class of agents, that are under evaluation as treatment of patients with non-small cell lung cancer (NSCLC).
The class of agents Garon finds exciting in the field of NSCLC is the KRAS G12C inhibitors. These agents have generating a lot of enthusiasm as the KRAS mutation is a very trackable target, and KRAS also appears to be very prevalent in NSCLC. Garon says KRAS is similar to EGFR mutations in terms of prevalence in NSCLC.
There is new data emerging now and clinical trials evaluating this target in NSCLC, Garon adds. It will be exciting to see how these therapies evolve as treatment of patients with NSCLC who may harbor a KRAS mutation.
<<View data for a novel KRAS G12C inhibitor as treatment of multiple solid tumors
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
January 20th 2025In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.
Read More
Roundtable Roundup: Lung Cancer Molecular Testing and ALK-Targeted Treatment
January 18th 2025In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options for a patient with metastatic non–small cell lung cancer (NSCLC), with participants.
Read More
Amivantamab/Lazertinib Maintains OS Benefit in EGFR+ NSCLC
January 15th 2025During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and toxicity management in patients with EGFR-mutated non–small cell lung cancer in the second article of a 2-part series.
Read More
